Form 4: Sanara MedTech Director Sara Ortwein Receives Restricted Stock Grant Under 2024 Incentive Plan

Sanara MedTech Inc. Director Sara N. Ortwein was granted 3,277 shares of restricted common stock as part of the company's 2024 Omnibus Long-Term Incentive Plan, aligning her interests with shareholder value.

Summary

• Sanara MedTech Inc. (SMTI) Director Sara N. Ortwein acquired 3,277 shares of common stock on May 22, 2025.
• The acquisition was a grant of restricted stock with a price of $0 per share.
• These shares were granted under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan.
• Following this transaction, Ms. Ortwein beneficially owns a total of 20,799 shares of common stock.
• The restricted shares are set to vest on the earlier of the 2026 annual shareholder meeting or May 22, 2026, contingent on Ms. Ortwein continuing to provide services to the Company.

Sentiment

Score: 6

Explanation: The grant of restricted stock to a director is generally a neutral to slightly positive event, as it aligns the director's interests with shareholders and is a standard component of compensation, indicating stability in governance.

Positives

• The grant of restricted stock to a director helps align management and director interests with those of shareholders, as the value of the grant is tied to the company's stock performance.
• The transaction is part of a pre-existing incentive plan (2024 Omnibus Long-Term Incentive Plan), indicating a structured approach to executive and director compensation.

Future Outlook

The restricted stock granted to Director Sara N. Ortwein is subject to future vesting conditions, specifically on the earlier of the 2026 annual shareholder meeting or May 22, 2026, provided she continues to provide services to the company.

Industry Context

This Form 4 filing represents a routine insider transaction, common across publicly traded companies, where equity is granted to directors or executives as part of their compensation and incentive structure. Such grants are standard practice in the healthcare technology sector, where Sanara MedTech operates, to retain talent and align interests.

Corporate Governance

Related Party Transactions

• The grant of restricted stock to Sara N. Ortwein, a director of Sanara MedTech Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of restricted stock is a form of equity compensation that can lead to minor dilution over time, but it also aims to align the director's interests with long-term shareholder value.
• Director (Sara N. Ortwein): Receives equity compensation, which incentivizes her continued service and performance tied to the company's stock price.

Next Steps

• The restricted shares granted to Sara N. Ortwein will vest on the earlier of the 2026 annual shareholder meeting or May 22, 2026, subject to continued service.

Key Dates

Keywords

Sanara MedTech, SMTI, Restricted Stock, Stock Grant, Director Compensation, SEC Form 4, Insider Transaction, Equity Incentive Plan, Corporate Governance